Protocol Ledger

NCT05327894 · Phase III · RECRUITING

Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

Interventional Phase III clinical trial protocol NCT05327894 sponsored by Princess Maxima Center for Pediatric Oncology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-12-15 Enrollment: 160 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05327894
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)160 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05327894
Protocol FieldVerified Registry Value
NCT IdentifierNCT05327894
Consolidated Lead SponsorPrincess Maxima Center for Pediatric Oncology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment160 participants (ESTIMATED)
Registered Start Date2022-12-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05327894
Hospital Research SiteLocationSite Profile
Queensland Children's HospitalSouth Brisbane, AustraliaOpen Hospital Dossier ->
Cliniques Universitaires Saint-LucBrussels, BelgiumOpen Hospital Dossier ->
Universitair Ziekenhuis GentGhent, BelgiumOpen Hospital Dossier ->
UZ LeuvenLeuven, BelgiumOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI